| www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html |  2.22.31.43 | 200 OK | 8.3 kB |
URL User Request GET HTTP/2www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html IP2.22.31.43:443 ASN#20940 Akamai International B.V.
CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeHTML document, Unicode text, UTF-8 text, with very long lines (8280), with CRLF line terminators Hash82d32a98efc0a70954af30f7bd2e9d46 3da5dd2b77e33c2293581fdf46aa858bd167b871 aeeccc980c4f220df66ab94b117c144cdf05516674a356f4a422e0eb338e5d7f
GET /news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Upgrade-Insecure-Requests: 1
Connection: keep-alive
Sec-Fetch-Dest: document
Sec-Fetch-Mode: navigate
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
content-type: text/html; charset=utf-8
last-modified: Fri, 29 Mar 2024 12:38:39 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
version: cloud
data-source: SC
x-frame-options: SAMEORIGIN
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 8282
cache-control: public, max-age=59
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
set-cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; path=/; secure; HttpOnly; SameSite=Lax
GNWTracker=0ed83357-ca28-4040-8b81-f499a5a894b6; expires=Thu, 28-Mar-2024 12:38:39 GMT; path=/; secure
__RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; path=/; secure; HttpOnly
ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:38 GMT; Max-Age=7199; HttpOnly
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/Content/css/bootstrap.min.css | 2.22.31.43 | 200 OK | 24 kB |
URL GET HTTP/2www.globenewswire.com/Content/css/bootstrap.min.css IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeASCII text, with very long lines (65319), with CRLF line terminators Hash24cc8c955358f312b3deb9f5c55d5744 4a41cf1be6840d26f6e8686fca052aa6225ec951 d8cf0e79a5090f2bd9fb04cc7036c415f43b6a9cbab6f522972ec05409f2652e
GET /Content/css/bootstrap.min.css HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: text/css,*/*;q=0.1
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: style
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/css
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 23800
cache-control: max-age=33242
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1 | 2.22.31.43 | 200 OK | 4.1 kB |
URL GET HTTP/2www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeASCII text, with very long lines (23908), with no line terminators Hash1e5cdb0d55d6ad927f67cfce3c03fa6b 31c2aacadeb316d000caba3e5be950eb846fa1e9 9ecc18ee346fef612ca208da85986ebe147aff879cedf07e67738842fad61527
GET /bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: text/css,*/*;q=0.1
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: style
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/css; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:53:03 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 4051
cache-control: public, max-age=31500864
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/react-styles?v=jWZLyoZm8k_QxnP_CKXyBMkGVdFEqJoNRFwH1d-VWK01 | 2.22.31.43 | 200 OK | 19 kB |
URL GET HTTP/2www.globenewswire.com/bundles/react-styles?v=jWZLyoZm8k_QxnP_CKXyBMkGVdFEqJoNRFwH1d-VWK01 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeUnicode text, UTF-8 text, with very long lines (34499), with CRLF line terminators Hash45c8650480bceecac97088064695c743 74c5555614012232357234dc255ed959cc60b3cb 3f4ce7edbfb53d595dc9d9b3fa742fe7bb6e3614dd31714aa8651dc8028a55e7
GET /bundles/react-styles?v=jWZLyoZm8k_QxnP_CKXyBMkGVdFEqJoNRFwH1d-VWK01 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: text/css,*/*;q=0.1
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: style
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/css; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:53:03 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 19367
cache-control: public, max-age=31500864
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/react-scripts?v=pF6EVQMdqPpJJJvbtJc1SfSUeed4MXqpaW43OCGbLJ01 | 2.22.31.43 | 200 OK | 275 kB |
URL GET HTTP/2www.globenewswire.com/bundles/react-scripts?v=pF6EVQMdqPpJJJvbtJc1SfSUeed4MXqpaW43OCGbLJ01 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeJavaScript source, Unicode text, UTF-8 text, with very long lines (65421), with no line terminators Size275 kB (274939 bytes) Hash03729649e4954c0f3257faa92d4d3d89 66990739cb0dbc66370cdee77510bd4ef0439741 fba14f4e0f5f2be0da4137e8bbd343a4b8aa49253d69474c2a51af535f0fab29
GET /bundles/react-scripts?v=pF6EVQMdqPpJJJvbtJc1SfSUeed4MXqpaW43OCGbLJ01 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/javascript; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:54:42 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 274939
cache-control: public, max-age=31500963
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 | 2.22.31.43 | 200 OK | 31 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 30928, version 1.0 Hashac0d2859ea5f8fd6bcb3c305c08ec184 7f6c17e3e592cd8bd346b9cc261d8dd961b8aef7 ae919a7c9f25f0fd97fc18e398ae8e453fcaae487e4a4cb4f896e7fecde4a780
GET /content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 30928
cache-control: max-age=33318
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/article-details-scripts?v=viPHOO9UNFR1NTO75vvRHa_af0nzJI9Y_LlhSgEGuLk1 | 2.22.31.43 | 200 OK | 3.9 kB |
URL GET HTTP/2www.globenewswire.com/bundles/article-details-scripts?v=viPHOO9UNFR1NTO75vvRHa_af0nzJI9Y_LlhSgEGuLk1 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeJavaScript source, ASCII text, with CRLF line terminators Hash19f84f1c6daaa69655e3936f44251ab4 1315a89464d677397a853266466fe7f836a5f05e 8972352d512f35a60722a8dd81f1c1104d695e9c000ed5aa3b9334af3b39e667
GET /bundles/article-details-scripts?v=viPHOO9UNFR1NTO75vvRHa_af0nzJI9Y_LlhSgEGuLk1 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/javascript; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:53:03 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 3940
cache-control: public, max-age=31500864
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/article-details-styles?v=B7wBZK9ShoV2QjVc4klr9JQc9l6pJBuzCZ_0R9ilKc01 | 2.22.31.43 | 200 OK | 2.8 kB |
URL GET HTTP/2www.globenewswire.com/bundles/article-details-styles?v=B7wBZK9ShoV2QjVc4klr9JQc9l6pJBuzCZ_0R9ilKc01 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeUnicode text, UTF-8 text, with very long lines (13997), with no line terminators Hash34499aea222d5b30fbacc6ed42287044 060ff5813c861073e7fbb314a7c528b05d8ce516 fbb71be6e710c4b6cca1ebf023d88cbe13faaf7adb26dce93572e851e2881b96
GET /bundles/article-details-styles?v=B7wBZK9ShoV2QjVc4klr9JQc9l6pJBuzCZ_0R9ilKc01 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: text/css,*/*;q=0.1
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: style
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/css; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:53:33 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 2770
cache-control: public, max-age=31500894
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/Scripts/stickyfill.min.js | 2.22.31.43 | 200 OK | 6.5 kB |
URL GET HTTP/2www.globenewswire.com/Scripts/stickyfill.min.js IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeJavaScript source, Unicode text, UTF-8 text, with very long lines (6374), with CRLF line terminators Hash68fa8e216f0402b97bfec67da3f9c9f0 6368f1b60dde126ff6a0d8fac2da5ad96ce9abb4 662057e4e885eae8071d9737d50902e9d41848e132935ec9963797501d3ce812
GET /Scripts/stickyfill.min.js HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/javascript
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-length: 6505
cache-control: max-age=33335
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/bundles/layout-jquery-scripts?v=TXkXsX7p7r9-AnnjDqFdUGhnEN2-r8TpYAaGbshNq4s1 | 2.22.31.43 | 200 OK | 32 kB |
URL GET HTTP/2www.globenewswire.com/bundles/layout-jquery-scripts?v=TXkXsX7p7r9-AnnjDqFdUGhnEN2-r8TpYAaGbshNq4s1 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeJavaScript source, Unicode text, UTF-8 text, with very long lines (65534), with no line terminators Hashc94ea43d1c85159023379d76f7c2ec2a 79b6c056a18d91bae4b7279fccca32ab32ff6df6 8034ff6b22f33ea8ed6ff34887c89e0951b4967a51f0cd4aeebcd042f24450a7
GET /bundles/layout-jquery-scripts?v=TXkXsX7p7r9-AnnjDqFdUGhnEN2-r8TpYAaGbshNq4s1 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: text/javascript; charset=utf-8
last-modified: Fri, 29 Mar 2024 02:53:03 GMT
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 31759
cache-control: public, max-age=31500864
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 | 2.22.31.43 | 200 OK | 31 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 30928, version 1.0 Hashac0d2859ea5f8fd6bcb3c305c08ec184 7f6c17e3e592cd8bd346b9cc261d8dd961b8aef7 ae919a7c9f25f0fd97fc18e398ae8e453fcaae487e4a4cb4f896e7fecde4a780
GET /content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: identity
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 30928
cache-control: max-age=33318
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 | 2.22.31.43 | 200 OK | 31 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 30928, version 1.0 Hashac0d2859ea5f8fd6bcb3c305c08ec184 7f6c17e3e592cd8bd346b9cc261d8dd961b8aef7 ae919a7c9f25f0fd97fc18e398ae8e453fcaae487e4a4cb4f896e7fecde4a780
GET /content/fonts/font-montserrat/JTUSjIg1_i6t8kCHKm459Wlhyw.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: identity
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 30928
cache-control: max-age=33318
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-montserrat/JTUQjIg1_i6t8kCHKm459WxRyS7m.woff2 | 2.22.31.43 | 200 OK | 32 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-montserrat/JTUQjIg1_i6t8kCHKm459WxRyS7m.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 31760, version 1.0 Hashfda4d0b623999af43148ba34c3b1ff73 ca5496af89720cc3e94e6279132f252b7cd471a6 33befdbbb24930584f5ac94ea3117adcd56518f20ab1619d05de83ffd1821d38
GET /content/fonts/font-montserrat/JTUQjIg1_i6t8kCHKm459WxRyS7m.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: identity
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 31760
cache-control: max-age=33278
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.googletagmanager.com/gtag/js?id=G-ERWPGTJ5X8 |  142.250.74.168 | 200 OK | 105 kB |
URL GET HTTP/2www.googletagmanager.com/gtag/js?id=G-ERWPGTJ5X8 IP142.250.74.168:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerGoogle Trust Services LLC Subject*.google-analytics.com FingerprintDE:42:E4:CC:E5:66:70:09:F3:E6:6E:57:B7:5E:22:0A:A3:03:C2:7C ValidityMon, 26 Feb 2024 08:03:40 GMT - Mon, 20 May 2024 08:03:39 GMT
File typeJavaScript source, ASCII text, with very long lines (7711) Size105 kB (104970 bytes) Hash541a15f70b2f24f3b6af55d9d2e5efbf 3a5dc81fa82393062c052e6c63fb6f69c8e7e166 0e9d1bfc7496b3d2c06338591adff27c30498ee694c47d84300e284621188ffb
GET /gtag/js?id=G-ERWPGTJ5X8 HTTP/1.1
Host: www.googletagmanager.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
content-type: application/javascript; charset=UTF-8
access-control-allow-origin: *
access-control-allow-credentials: true
access-control-allow-headers: Cache-Control
content-encoding: br
vary: Accept-Encoding
date: Fri, 29 Mar 2024 12:38:39 GMT
expires: Fri, 29 Mar 2024 12:38:39 GMT
cache-control: private, max-age=900
strict-transport-security: max-age=31536000; includeSubDomains
cross-origin-resource-policy: cross-origin
server: Google Tag Manager
content-length: 104970
x-xss-protection: 0
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/static/sys/1711715919801 | 2.22.31.43 | 200 OK | 807 B |
URL GET HTTP/2www.globenewswire.com/static/sys/1711715919801 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hashec8f47fd26c84dbc30d1291bc1bbd6f6 1b6ea219dadefd69c2f720794d618fbb30499ac8 15e1b9c9074d83371b76b454eab03a8dcb90d30c45d5bac0b539c4d01954c249
GET /static/sys/1711715919801 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json; charset=utf-8
last-modified: Fri, 29 Mar 2024 12:38:39 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-length: 807
cache-control: public, no-store
date: Fri, 29 Mar 2024 12:38:39 GMT
set-cookie: GNWTracker=e688dcf9-ada7-4d46-be89-7a7acd6ef03d; expires=Thu, 28-Mar-2024 12:38:39 GMT; path=/; secure
bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhX0nIaOAQAAOSg4ihe1RpVDGtuan1LRZzrzZGDcABIs/7cCzSfoyOyojcE/9ndlJPXdRpccgkA7z74ACjQZBGudNiF6bO56GreOnYMKpCP+YfuwwgzN9eIpm0cyDpODn0mxmrEPeVgGnQAeEq+5AL58XQDiP1oQpqvi04O4Ti/VeK4Gl832RxG9vXOx7u9g9GrC5qgE7Vq9TP/MgclezgOs9XoKdwGGgrqkqzBkGfAFLbFWdjGi3fuB2g8b/3tg8A==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7200; Secure
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/logo/color.svg | 2.22.31.43 | 200 OK | 5.4 kB |
URL GET HTTP/2www.globenewswire.com/content/logo/color.svg IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeSVG Scalable Vector Graphics image Hashd89d965aea6b3583cc42fff9603a76c5 6b2e9a88ca296633b50d21ba4a1cdad0a71b7e1c 4d7823ba7a38937db003a9603489792b6093e20a534b5b27bdc9ad92c00e4857
GET /content/logo/color.svg HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhX0nIaOAQAAOSg4ihe1RpVDGtuan1LRZzrzZGDcABIs/7cCzSfoyOyojcE/9ndlJPXdRpccgkA7z74ACjQZBGudNiF6bO56GreOnYMKpCP+YfuwwgzN9eIpm0cyDpODn0mxmrEPeVgGnQAeEq+5AL58XQDiP1oQpqvi04O4Ti/VeK4Gl832RxG9vXOx7u9g9GrC5qgE7Vq9TP/MgclezgOs9XoKdwGGgrqkqzBkGfAFLbFWdjGi3fuB2g8b/3tg8A==~1
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: image/svg+xml
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 5364
cache-control: max-age=33415
date: Fri, 29 Mar 2024 12:38:39 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| ml.globenewswire.com/media/ZjNiODE2MDMtNGE2MC00MTIyLTk4YWItYTRiNmExMGZlYTIwLTEwMjkwMDU=/tiny/Mesoblast-Limited.png | 104.84.152.185 | 200 OK | 35 B |
URL GET HTTP/2ml.globenewswire.com/media/ZjNiODE2MDMtNGE2MC00MTIyLTk4YWItYTRiNmExMGZlYTIwLTEwMjkwMDU=/tiny/Mesoblast-Limited.png IP104.84.152.185:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectpro.globenewswire.com Fingerprint1D:D0:76:84:34:F0:F2:04:81:9D:DA:8C:7D:2E:A1:EE:05:C0:3F:F5 ValidityFri, 16 Feb 2024 16:14:02 GMT - Thu, 16 May 2024 16:14:01 GMT
File typeGIF image data, version 89a, 1 x 1 Hashc2196de8ba412c60c22ab491af7b1409 5fbd472222feb8a22cf5b8aa5dc5b8e13af88e2b 6adc3d4c1056996e4e8b765a62604c78b1f867cceb3b15d0b9bedb7c4857f992
GET /media/ZjNiODE2MDMtNGE2MC00MTIyLTk4YWItYTRiNmExMGZlYTIwLTEwMjkwMDU=/tiny/Mesoblast-Limited.png HTTP/1.1
Host: ml.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
DNT: 1
Connection: keep-alive
Cookie: ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
pragma: no-cache
content-type: image/png
x-content-type-options: nosniff
x-frame-options: ALLOWALL
x-xss-protection: 1; mode=block
content-length: 35
cache-control: no-cache, no-store, must-revalidate
expires: Fri, 29 Mar 2024 12:38:39 GMT
date: Fri, 29 Mar 2024 12:38:39 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/quick-search-filters/en | 2.22.31.43 | 200 OK | 626 B |
URL GET HTTP/2www.globenewswire.com/quick-search-filters/en IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hasheb816ba626a30150bc9ff64bc606c963 6054eed64f88dc07e53ff41fe9b78dd73b59f820 dbd6148bafc4332096016293c576cafeef411e6f56db059efd01f9b40cfaf0a5
GET /quick-search-filters/en HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhX0nIaOAQAAOSg4ihe1RpVDGtuan1LRZzrzZGDcABIs/7cCzSfoyOyojcE/9ndlJPXdRpccgkA7z74ACjQZBGudNiF6bO56GreOnYMKpCP+YfuwwgzN9eIpm0cyDpODn0mxmrEPeVgGnQAeEq+5AL58XQDiP1oQpqvi04O4Ti/VeK4Gl832RxG9vXOx7u9g9GrC5qgE7Vq9TP/MgclezgOs9XoKdwGGgrqkqzBkGfAFLbFWdjGi3fuB2g8b/3tg8A==~1
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json; charset=utf-8
last-modified: Fri, 29 Mar 2024 12:34:28 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
data-source: SC
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 626
cache-control: public, max-age=339
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
set-cookie: bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhf0nIaOAQAAjSg4ihfgN/tbNM/Kg+8rabvRkSv0Fvb62QTbO7kF+IZDlIZMQL8gr3CXn2+8GvZwp0KgicZkdSA0f6DkMCH6cXdHb452V5gd5jWzp8iSgZQGf82UgoLoLrax8AZbV/xpZIQ3ylLUbLmtzj90Eegzcs6ws1qtYzoHbpMjnyiAOSwqTVFXhc1z1TfpiMtZyrx99JENHzz1nmhkHFUqgRCPcZCPxNSYgEUJwLQ2HG419T4uqIEkk2EdfA==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7199; Secure
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/scripttemplates/otSDKStub.js |  104.19.177.52 | 200 OK | 6.8 kB |
URL GET HTTP/2cdn.cookielaw.org/scripttemplates/otSDKStub.js IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
File typeJavaScript source, ASCII text, with very long lines (21099) Hash371fe1fde25dc853add509f5d9fe57ac b6219c34246fa4a3f1f35c64bbd708dc04c463ca 92e4588c227a58321a728574129e52ec244df30b90fc9a64a30ee65410104c41
GET /scripttemplates/otSDKStub.js HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/javascript
content-length: 6839
content-encoding: gzip
content-md5: Pg1MHDpg+UGdovxhidM4Kg==
last-modified: Thu, 28 Mar 2024 12:31:00 GMT
etag: 0x8DC4F22ED3FADA7
x-ms-request-id: 160a017d-601e-0064-5d2a-81c81b000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 19452
accept-ranges: bytes
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb141d4eb509-OSL
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/Home/siteheader/en | 2.22.31.43 | 200 OK | 827 B |
URL GET HTTP/2www.globenewswire.com/Home/siteheader/en IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hash6457ea3868da321fa5c6e21e1fddd202 84a3fd9e333d6bd9105805d4d585e0876b091e8f 13e4088bcb0c440b2fb8cb521e9152c0f2764ef10b09613cb526426ca8ac027f
GET /Home/siteheader/en HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhX0nIaOAQAAOSg4ihe1RpVDGtuan1LRZzrzZGDcABIs/7cCzSfoyOyojcE/9ndlJPXdRpccgkA7z74ACjQZBGudNiF6bO56GreOnYMKpCP+YfuwwgzN9eIpm0cyDpODn0mxmrEPeVgGnQAeEq+5AL58XQDiP1oQpqvi04O4Ti/VeK4Gl832RxG9vXOx7u9g9GrC5qgE7Vq9TP/MgclezgOs9XoKdwGGgrqkqzBkGfAFLbFWdjGi3fuB2g8b/3tg8A==~1
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json
last-modified: Fri, 29 Mar 2024 12:33:49 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 827
cache-control: public, max-age=30
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
set-cookie: bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhj0nIaOAQAAmyg4ihfuQUkhy76YK9Ci4rOzqDPdi5xyi3eghVVCm1TM8QN+JJaU35RYLq3RVKDlkxPWHKuuKrGz28JVeMmTrQu0LA4lmI5Pb3PasO/c1Qj/88qM2RQkrag/L5b9R9lo9OEDQ+h9Eg88UrjNEU3epMF3Eu2Ouh+tajpHR0Rx8m0UjT/LYSwpnWa/MEywq/v/e5OgWuco+HolHhOnqKU96Ry8N0GKPuD0KsMkts6VviRc23OzrK/BDQ==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7199; Secure
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/Home/sitefooter/en?v=803 | 2.22.31.43 | 200 OK | 2.8 kB |
URL GET HTTP/2www.globenewswire.com/Home/sitefooter/en?v=803 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hash5f896ebc4eb72a31136e6c239a646fb4 69e9aceb269cbbe0ce5a3964f3dc2226aad34926 3edd2ba5879ef697ddca8ad1ee7ff670e8b7a7cfe1b5071f8c13d8752dd4918c
GET /Home/sitefooter/en?v=803 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhX0nIaOAQAAOSg4ihe1RpVDGtuan1LRZzrzZGDcABIs/7cCzSfoyOyojcE/9ndlJPXdRpccgkA7z74ACjQZBGudNiF6bO56GreOnYMKpCP+YfuwwgzN9eIpm0cyDpODn0mxmrEPeVgGnQAeEq+5AL58XQDiP1oQpqvi04O4Ti/VeK4Gl832RxG9vXOx7u9g9GrC5qgE7Vq9TP/MgclezgOs9XoKdwGGgrqkqzBkGfAFLbFWdjGi3fuB2g8b/3tg8A==~1
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json
last-modified: Fri, 29 Mar 2024 12:34:26 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-length: 2785
cache-control: public, max-age=24
date: Fri, 29 Mar 2024 12:38:40 GMT
set-cookie: bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhn0nIaOAQAAoCg4ihfriFQrk7MxobNgMAgpFcgQD4Qh/IgVHOM0GsmsyitkNj3Y7ME+a1kMZqMtXq5EwlSovP+xWHtVj51rONy2FDvAD/3vFeFhyoxrJVhj31WmJXGwvh5EkFDAShPqUCeTsbKMOVpgoh/m1Vq2La2pAl86UnPVcKeQT/Q64c0BPxJw6UdK/QqarL6Yt3Xw6vnNRWU/MiHMzM+ehJ9iCdfRfdCbdOSOvg0aFufUPERzGbcAnPHAHA==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7199; Secure
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 | 2.22.31.43 | 200 OK | 128 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 128352, version 1.0 Size128 kB (128352 bytes) Hash53436aca8627a49f4deaaa44dc9e3c05 0bc0c675480d94ec7e8609dda6227f88c5d08d2c 8265f64786397d6b832d1ca0aafdf149ad84e72759fffa9f7272e91a0fb015d1
GET /content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: identity
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhf0nIaOAQAAjSg4ihfgN/tbNM/Kg+8rabvRkSv0Fvb62QTbO7kF+IZDlIZMQL8gr3CXn2+8GvZwp0KgicZkdSA0f6DkMCH6cXdHb452V5gd5jWzp8iSgZQGf82UgoLoLrax8AZbV/xpZIQ3ylLUbLmtzj90Eegzcs6ws1qtYzoHbpMjnyiAOSwqTVFXhc1z1TfpiMtZyrx99JENHzz1nmhkHFUqgRCPcZCPxNSYgEUJwLQ2HG419T4uqIEkk2EdfA==~1
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 128352
cache-control: max-age=33311
date: Fri, 29 Mar 2024 12:38:40 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/api/article/explore/en/False | 2.22.31.43 | 200 OK | 1.3 kB |
URL GET HTTP/2www.globenewswire.com/api/article/explore/en/False IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hashfeada4f99229cd86b20f1ec0bcfef521 3ea88fc65495d1f7f983a141760411bb3583b993 884fd7b85e5fa165230d09e08b1a0ea7adcc17bed71bafc99241d3a1ab9d26f0
GET /api/article/explore/en/False HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Content-Type: application/json
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhf0nIaOAQAAjSg4ihfgN/tbNM/Kg+8rabvRkSv0Fvb62QTbO7kF+IZDlIZMQL8gr3CXn2+8GvZwp0KgicZkdSA0f6DkMCH6cXdHb452V5gd5jWzp8iSgZQGf82UgoLoLrax8AZbV/xpZIQ3ylLUbLmtzj90Eegzcs6ws1qtYzoHbpMjnyiAOSwqTVFXhc1z1TfpiMtZyrx99JENHzz1nmhkHFUqgRCPcZCPxNSYgEUJwLQ2HG419T4uqIEkk2EdfA==~1
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json; charset=utf-8
last-modified: Fri, 29 Mar 2024 12:38:14 GMT
etag: "8d5e5235-0990-4e17-9e98-e6a74422f783"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 1265
cache-control: max-age=15
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
set-cookie: bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhr0nIaOAQAA8Sg4ihcdF1X/PaqUFf97uGRA2IhTO15oSgnTfACr0qywm3PanQSRdyuku567TIXUyC3hD30emFXJVhoW09q0Lut/b69rO0CzWkUKIsloid821EMeMq/zdebr2kuMztxFJydOM4Fz5ZRCkSlsGTx5zDPUvWPMVCVMn+Rcyou+0eTmbjF/MG6JV5p7VTYaRd7wpASmzhsOFGe3PbsQJh5Hx9d3IFb77ihqvrxSZ7Ykzwyu6TfGkqetTA==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7199; Secure
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/93ab55d0-5227-4b5f-9baa-7c0805ac9eec.json | 104.19.177.52 | 200 OK | 1.8 kB |
URL GET HTTP/2cdn.cookielaw.org/consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/93ab55d0-5227-4b5f-9baa-7c0805ac9eec.json IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
Hasheceeec9a79c87b60819509aa3b629c83 33ea4cc082e8296a85b78e761e1a43ae1bd2f176 c219d92dab340176db49003be17422810cb44145dc586cfba7c2f9d1a965539a
GET /consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/93ab55d0-5227-4b5f-9baa-7c0805ac9eec.json HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/x-javascript
content-length: 1798
cf-ray: 86bfeb14ce687131-OSL
cf-cache-status: HIT
accept-ranges: bytes
access-control-allow-origin: *
age: 73427
cache-control: public, max-age=86400
content-encoding: gzip
etag: 0x8DBE6D2AA42F1C1
expires: Sat, 30 Mar 2024 12:38:40 GMT
last-modified: Thu, 16 Nov 2023 18:34:27 GMT
strict-transport-security: max-age=31536000; includeSubDomains; preload
vary: Accept-Encoding
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Cache-Control,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
content-md5: v7f0ftr/zAc42eFne2T+4A==
x-content-type-options: nosniff
x-ms-blob-type: BlockBlob
x-ms-lease-status: unlocked
x-ms-request-id: 0bb4f9b7-701e-008c-0f0f-2f518d000000
x-ms-version: 2009-09-19
server: cloudflare
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/logo/footer.svg | 2.22.31.43 | 200 OK | 4.4 kB |
URL GET HTTP/2www.globenewswire.com/content/logo/footer.svg IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeSVG Scalable Vector Graphics image Hash67f2ad8021701983b97bbd092b2816cf b24ab0596352052461615eae2d69bf155794d642 5ae6d318915e2173dd7cab6564bc5c71051c05dca7ad3c4b99bf5525bf3422ca
GET /content/logo/footer.svg HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhr0nIaOAQAA8Sg4ihcdF1X/PaqUFf97uGRA2IhTO15oSgnTfACr0qywm3PanQSRdyuku567TIXUyC3hD30emFXJVhoW09q0Lut/b69rO0CzWkUKIsloid821EMeMq/zdebr2kuMztxFJydOM4Fz5ZRCkSlsGTx5zDPUvWPMVCVMn+Rcyou+0eTmbjF/MG6JV5p7VTYaRd7wpASmzhsOFGe3PbsQJh5Hx9d3IFb77ihqvrxSZ7Ykzwyu6TfGkqetTA==~1; _ga_ERWPGTJ5X8=GS1.1.1711715920.1.0.1711715920.60.0.0; _ga=GA1.1.658054844.1711715920
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: image/svg+xml
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 4379
cache-control: max-age=33337
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| ml.globenewswire.com/Resource/Download/a9938a8a-a0ba-4708-abd5-2219515343fc?size=3 | 104.84.152.185 | 200 OK | 3.4 kB |
URL GET HTTP/2ml.globenewswire.com/Resource/Download/a9938a8a-a0ba-4708-abd5-2219515343fc?size=3 IP104.84.152.185:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectpro.globenewswire.com Fingerprint1D:D0:76:84:34:F0:F2:04:81:9D:DA:8C:7D:2E:A1:EE:05:C0:3F:F5 ValidityFri, 16 Feb 2024 16:14:02 GMT - Thu, 16 May 2024 16:14:01 GMT
File typePNG image data, 289 x 38, 8-bit/color RGBA, non-interlaced Hash7f976cb8914bc72b546f40f66cf7f898 433b08e477b424967caa548e72785b19e672acf1 aef245ec2d526bcaab39082aef875743ee3c2a89dc1380b14c093b0ac14efac4
GET /Resource/Download/a9938a8a-a0ba-4708-abd5-2219515343fc?size=3 HTTP/1.1
Host: ml.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Cookie: ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhf0nIaOAQAAjSg4ihfgN/tbNM/Kg+8rabvRkSv0Fvb62QTbO7kF+IZDlIZMQL8gr3CXn2+8GvZwp0KgicZkdSA0f6DkMCH6cXdHb452V5gd5jWzp8iSgZQGf82UgoLoLrax8AZbV/xpZIQ3ylLUbLmtzj90Eegzcs6ws1qtYzoHbpMjnyiAOSwqTVFXhc1z1TfpiMtZyrx99JENHzz1nmhkHFUqgRCPcZCPxNSYgEUJwLQ2HG419T4uqIEkk2EdfA==~1
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: image/png
last-modified: Fri, 29 Mar 2024 12:38:40 GMT
x-content-type-options: nosniff
access-control-allow-origin: *
source: v2
content-disposition: inline; filename=mesologo.png
x-frame-options: ALLOWALL
x-xss-protection: 1; mode=block
content-length: 3422
cache-control: public, max-age=100
expires: Fri, 29 Mar 2024 12:40:20 GMT
date: Fri, 29 Mar 2024 12:38:40 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 | 2.22.31.43 | 200 OK | 128 kB |
URL GET HTTP/2www.globenewswire.com/content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeWeb Open Font Format (Version 2), TrueType, length 128352, version 1.0 Size128 kB (128352 bytes) Hash53436aca8627a49f4deaaa44dc9e3c05 0bc0c675480d94ec7e8609dda6227f88c5d08d2c 8265f64786397d6b832d1ca0aafdf149ad84e72759fffa9f7272e91a0fb015d1
GET /content/fonts/font-material-icons/material-icons-v140-latin-regular.woff2 HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/font-woff2;q=1.0,application/font-woff;q=0.9,*/*;q=0.8
Accept-Language: en-US,en;q=0.5
Accept-Encoding: identity
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/bundles/pnr-global-styles?v=A0brblX3qGk5GycPhAO5iwvNrMX0iNCXDAzArFbHgVk1
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhr0nIaOAQAA8Sg4ihcdF1X/PaqUFf97uGRA2IhTO15oSgnTfACr0qywm3PanQSRdyuku567TIXUyC3hD30emFXJVhoW09q0Lut/b69rO0CzWkUKIsloid821EMeMq/zdebr2kuMztxFJydOM4Fz5ZRCkSlsGTx5zDPUvWPMVCVMn+Rcyou+0eTmbjF/MG6JV5p7VTYaRd7wpASmzhsOFGe3PbsQJh5Hx9d3IFb77ihqvrxSZ7Ykzwyu6TfGkqetTA==~1; _ga_ERWPGTJ5X8=GS1.1.1711715920.1.0.1711715920.60.0.0; _ga=GA1.1.658054844.1711715920
Sec-Fetch-Dest: font
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: font/woff2
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
access-control-allow-origin: *
content-length: 128352
cache-control: max-age=33311
date: Fri, 29 Mar 2024 12:38:40 GMT
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/api/article/recommended/D0cdfVe-Qaijs9sBkFK0Xw==/2852084/en | 2.22.31.43 | 200 OK | 876 B |
URL GET HTTP/2www.globenewswire.com/api/article/recommended/D0cdfVe-Qaijs9sBkFK0Xw==/2852084/en IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
Hash96fb71d7fa330c7a72bf145a696612c0 6607ddfea179c994348e3e725bcfba06b94e4423 293126ded26f27cc6b5d499b9bfc32b159e2549a053e9f8b16160d105fbdf7c8
GET /api/article/recommended/D0cdfVe-Qaijs9sBkFK0Xw==/2852084/en HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Content-Type: application/json
DNT: 1
Connection: keep-alive
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhf0nIaOAQAAjSg4ihfgN/tbNM/Kg+8rabvRkSv0Fvb62QTbO7kF+IZDlIZMQL8gr3CXn2+8GvZwp0KgicZkdSA0f6DkMCH6cXdHb452V5gd5jWzp8iSgZQGf82UgoLoLrax8AZbV/xpZIQ3ylLUbLmtzj90Eegzcs6ws1qtYzoHbpMjnyiAOSwqTVFXhc1z1TfpiMtZyrx99JENHzz1nmhkHFUqgRCPcZCPxNSYgEUJwLQ2HG419T4uqIEkk2EdfA==~1
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: application/json; charset=utf-8
last-modified: Fri, 29 Mar 2024 12:38:40 GMT
etag: "93f3f1c9-832b-42a5-8717-768a722e63ca"
x-content-type-options: nosniff
data-source: SC
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 876
cache-control: max-age=600
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
set-cookie: bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhz0nIaOAQAA9ik4ihePabOSgZvyu3S8pEwecwMCg4gyDLMGOmeuTLn2s8rMy2aM1jh8Q4+dapy1OuvHNzyT5JhriXdAw7OTFHSd6UeJncbAwjMnF63mnVMAmnz2pnirPwmcS4v8iivZnPlxHLYNwTzcJZ7KZMkMw5+1qLK+Jefa+v/RxpgoedOv1OhGoCGyM8KSlC5tF5hR54tkexyKDjMoaUhj/TXegDdpHU9b9LRt+lQvMKdiLV+wy2wjg0hV0Q==~1; Domain=.globenewswire.com; Path=/; Expires=Fri, 29 Mar 2024 14:38:39 GMT; Max-Age=7199; Secure
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/scripttemplates/202310.1.0/otBannerSdk.js | 104.19.177.52 | 200 OK | 105 kB |
URL GET HTTP/2cdn.cookielaw.org/scripttemplates/202310.1.0/otBannerSdk.js IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
File typeJavaScript source, ASCII text, with very long lines (65451) Size105 kB (104832 bytes) Hashc9a77361da3fe2addf7b59fb1c5eacd7 54f1762eb1ed72eb862d2d0f019659d48b1c689d feeb83e3a11fb74465e062a5081f1f6f573ef66197f218a3a86447fefe3166f6
GET /scripttemplates/202310.1.0/otBannerSdk.js HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: script
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/javascript
content-length: 104832
content-encoding: gzip
content-md5: 1/fYiRcAkidM+2Rc1fEXtg==
last-modified: Thu, 26 Oct 2023 03:35:14 GMT
etag: 0x8DBD5D490C850BD
x-ms-request-id: fbbc7bb8-101e-0041-2a9a-226167000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 36528
accept-ranges: bytes
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb167f92b509-OSL
X-Firefox-Spdy: h2
|
|
| www.globenewswire.com/Content/logo/favicon.ico | 2.22.31.43 | 200 OK | 5.0 kB |
URL GET HTTP/2www.globenewswire.com/Content/logo/favicon.ico IP2.22.31.43:443 ASN#20940 Akamai International B.V.
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerLet's Encrypt Subjectrss.globenewswire.com Fingerprint94:F2:2B:1F:E0:EF:5A:17:6E:90:DC:AB:5D:0B:68:C8:71:89:CE:5C ValidityMon, 05 Feb 2024 04:23:30 GMT - Sun, 05 May 2024 04:23:29 GMT
File typeMS Windows icon resource - 3 icons, 16x16, 32 bits/pixel, 32x32, 32 bits/pixel Hash68876d0e3747d1a39df3d8209a89daa5 dcd4da038978a9cef06364821c7a7345414bdd2f 29134a8a616dcb607149bfdd299bb61c8b39f7c77cff5eaeb077fa20bd700c60
GET /Content/logo/favicon.ico HTTP/1.1
Host: www.globenewswire.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
Cookie: ASP.NET_SessionId=dt2fahfxashwomfi3ipbsp30; __RequestVerificationToken=R7MxknHprSsa6MaAfbHmxbzuKTI5JsWx6niEDP0jcec4wFFIIqFZVGjqM7yQuclYeHHKn9xnUIUBzXXViOizddCLK9g1; ak_bmsc=B2CE98D61252AD27312468D99F3C7B55~000000000000000000000000000000~YAAQJx8WAhH0nIaOAQAA+yU4ihcGMmrkJmkuqqrsg9B+X6W/T/9mq0BAsQNhr5E5c47ESfHFVe0we6uYi2iIawr+sjNEs5iYVOUBDkecPw0vTfLz1vCtrWhJTbjQrpuMzXohNQmnfAxkVhE6rhOvgFeCcwENbeGvvzqvCBx3nVLmq2U7tYDxT0VsmEaQWZ4ywjP8EEw8MUZd7oJECOLO88NvqtDUdT8NnSi5BmTOQrFhwN9J85KeOFtDbwgzpDT7XnyIVKm0F5Lr4tlk52iny2L9Vkn3v3ibAaWlq1UqedoAH2VUNqeuIzJV6tnD/kZwy5eqzE2nKdqMPl3buUIPjeEV139q7DAKZj43yCzG174Po5wu1aWGqHbfvaUEoBumvJ1mvunPNRXB9CfbefAXiQ==; bm_sv=29EC7687B7E19E183CE8F846A547BBF4~YAAQJx8WAhz0nIaOAQAA9ik4ihePabOSgZvyu3S8pEwecwMCg4gyDLMGOmeuTLn2s8rMy2aM1jh8Q4+dapy1OuvHNzyT5JhriXdAw7OTFHSd6UeJncbAwjMnF63mnVMAmnz2pnirPwmcS4v8iivZnPlxHLYNwTzcJZ7KZMkMw5+1qLK+Jefa+v/RxpgoedOv1OhGoCGyM8KSlC5tF5hR54tkexyKDjMoaUhj/TXegDdpHU9b9LRt+lQvMKdiLV+wy2wjg0hV0Q==~1; _ga_ERWPGTJ5X8=GS1.1.1711715920.1.0.1711715920.60.0.0; _ga=GA1.1.658054844.1711715920
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: same-origin
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
content-type: image/x-icon
last-modified: Thu, 21 Mar 2024 21:04:52 GMT
accept-ranges: bytes
etag: "0f2bd6ad37bda1:0"
x-content-type-options: nosniff
strict-transport-security: max-age=31536000; includeSubDomains; preload
content-encoding: gzip
content-length: 5027
cache-control: max-age=33397
date: Fri, 29 Mar 2024 12:38:40 GMT
vary: Accept-Encoding
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/c46a27bd-d53e-4858-b466-b33dc95a2041/en.json | 104.19.177.52 | 200 OK | 12 kB |
URL GET HTTP/2cdn.cookielaw.org/consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/c46a27bd-d53e-4858-b466-b33dc95a2041/en.json IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
Hash48cd3a001a59c417865bd8953fc28a68 b1c5bec6d108fbbf1d62284acdfdf4a714ffc164 e1a6c28011e8a54efad91d18bc352b30e406efcaf98f0fa31a91fb31412db597
GET /consent/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/c46a27bd-d53e-4858-b466-b33dc95a2041/en.json HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/x-javascript
content-length: 11482
cf-ray: 86bfeb16f8d57131-OSL
cf-cache-status: HIT
accept-ranges: bytes
access-control-allow-origin: *
age: 68462
cache-control: public, max-age=86400
content-encoding: gzip
etag: 0x8DBE6D2B4C74B8F
expires: Sat, 30 Mar 2024 12:38:40 GMT
last-modified: Thu, 16 Nov 2023 18:34:45 GMT
strict-transport-security: max-age=31536000; includeSubDomains; preload
vary: Accept-Encoding
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Cache-Control,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
content-md5: a5DnkbFXpHX2pnfqU3tfeg==
x-content-type-options: nosniff
x-ms-blob-type: BlockBlob
x-ms-lease-status: unlocked
x-ms-request-id: 6557a9e3-801e-007c-390f-2f177c000000
x-ms-version: 2009-09-19
server: cloudflare
X-Firefox-Spdy: h2
|
|
| www.google.no/ads/ga-audiences?v=1&t=sr&slf_rd=1&_r=4&tid=G-ERWPGTJ5X8&cid=658054844.1711715920>m=45je43r0v9111814984za200&aip=1&dma=1&dma_cps=sypham&gcd=13l3l3l2l1&npa=1&z=1222393671 | 142.250.74.131 | 200 OK | 42 B |
URL GET HTTP/2www.google.no/ads/ga-audiences?v=1&t=sr&slf_rd=1&_r=4&tid=G-ERWPGTJ5X8&cid=658054844.1711715920>m=45je43r0v9111814984za200&aip=1&dma=1&dma_cps=sypham&gcd=13l3l3l2l1&npa=1&z=1222393671 IP142.250.74.131:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerGoogle Trust Services LLC Subject*.google.no FingerprintBD:FC:1B:6B:7D:09:A2:62:4F:C6:C8:69:25:38:B5:AC:B1:42:C8:2E ValidityMon, 26 Feb 2024 08:21:28 GMT - Mon, 20 May 2024 08:21:27 GMT
File typeGIF image data, version 89a, 1 x 1 Hashd89746888da2d9510b64a9f031eaecd5 d5fceb6532643d0d84ffe09c40c481ecdf59e15a ef1955ae757c8b966c83248350331bd3a30f658ced11f387f8ebf05ab3368629
GET /ads/ga-audiences?v=1&t=sr&slf_rd=1&_r=4&tid=G-ERWPGTJ5X8&cid=658054844.1711715920>m=45je43r0v9111814984za200&aip=1&dma=1&dma_cps=sypham&gcd=13l3l3l2l1&npa=1&z=1222393671 HTTP/1.1
Host: www.google.no
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
p3p: policyref="https://www.googleadservices.com/pagead/p3p.xml", CP="NOI DEV PSA PSD IVA IVD OTP OUR OTR IND OTC"
timing-allow-origin: *
cross-origin-resource-policy: cross-origin
date: Fri, 29 Mar 2024 12:38:40 GMT
pragma: no-cache
expires: Fri, 01 Jan 1990 00:00:00 GMT
cache-control: no-cache, no-store, must-revalidate
content-type: image/gif
x-content-type-options: nosniff
server: cafe
content-length: 42
x-xss-protection: 0
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otFloatingRoundedIcon.json | 104.19.177.52 | 200 OK | 3.8 kB |
URL GET HTTP/2cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otFloatingRoundedIcon.json IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
Hashaa7aa84a0510fb7b91b4038e4b066a11 fb807267e7ea67ebdf430a775f5cf646b6262c56 3242e45a0994ce805cf2da7be63ccf7e1fd0254ea3a8b603d83dafe1325fea8e
GET /scripttemplates/202310.1.0/assets/otFloatingRoundedIcon.json HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/json
content-length: 3814
content-encoding: gzip
content-md5: hTmfcyiTxTg6KcEIhn07lw==
last-modified: Thu, 26 Oct 2023 03:35:08 GMT
etag: 0x8DBD5D48D9A1FE5
x-ms-request-id: a4be9653-001e-0072-270f-2f3ecc000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 68461
accept-ranges: bytes
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb17591a7131-OSL
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otCookieSettingsButton.json | 104.19.177.52 | 200 OK | 1.8 kB |
URL GET HTTP/2cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otCookieSettingsButton.json IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
Hashe6872c90592c095ac4b05fc37cb2f2c0 b71b3312ec6bd7cbaadd947cc95042496e0410f3 509f2e49500fbaeb5d7e1959071f2922b693d0135080e2871e124ec8bdd08bb2
GET /scripttemplates/202310.1.0/assets/otCookieSettingsButton.json HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/json
content-length: 1766
content-encoding: gzip
content-md5: yNa6Yc29I7rm/gwCvWCQmw==
last-modified: Thu, 26 Oct 2023 03:35:09 GMT
etag: 0x8DBD5D48E0FDA7F
x-ms-request-id: f382c3b9-701e-0057-510f-2f97b0000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Content-Encoding,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 68461
accept-ranges: bytes
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb17691c7131-OSL
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/logos/858612ad-0fdf-4c0e-bff5-0a12d5b345d4/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/502504fc-c710-466f-be08-10ab395f7c6c/Trillium_50x50.png | 104.19.177.52 | 200 OK | 1.8 kB |
URL GET HTTP/2cdn.cookielaw.org/logos/858612ad-0fdf-4c0e-bff5-0a12d5b345d4/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/502504fc-c710-466f-be08-10ab395f7c6c/Trillium_50x50.png IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
File typePNG image data, 50 x 50, 8-bit/color RGBA, non-interlaced Hash77e695d15d3d57f67b46ebddb9ad24b5 1c5c2384758f2508a499d9a4cdb69e8f490461f5 7220e138374824b0e3c41f01e083c179f6f3c5effdd9edb54b52817ab9feee47
GET /logos/858612ad-0fdf-4c0e-bff5-0a12d5b345d4/93ab55d0-5227-4b5f-9baa-7c0805ac9eec/502504fc-c710-466f-be08-10ab395f7c6c/Trillium_50x50.png HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
TE: trailers
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: image/png
content-length: 1816
content-md5: d+aV0V09V/Z7Ruvdua0ktQ==
last-modified: Thu, 19 Oct 2023 02:13:45 GMT
etag: 0x8DBD049061888B9
x-ms-request-id: 3f26cae7-e01e-006a-4103-26e1ab000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 64187
accept-ranges: bytes
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb1788bdb509-OSL
X-Firefox-Spdy: h2
|
|
| region1.analytics.google.com/g/collect?v=2&tid=G-ERWPGTJ5X8>m=45je43r0v9111814984za200&_p=1711715919629&_gaz=1&gcd=13l3l3l2l1&npa=1&dma_cps=sypham&dma=1&cid=658054844.1711715920&ul=en-us&sr=1280x1024&pscdl=noapi&_s=1&sid=1711715920&sct=1&seg=0&dl=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F03%2F26%2F2852084%2F0%2Fen%2FUnited-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html&dt=United%20States%20Food%20%26%20Drug%20Administration%20(FDA)%20Notifies&en=page_view&_fv=1&_nsi=1&_ss=1&_ee=1&tfd=1306 | 216.239.34.36 | 204 No Content | 0 B |
URL POST HTTP/2region1.analytics.google.com/g/collect?v=2&tid=G-ERWPGTJ5X8>m=45je43r0v9111814984za200&_p=1711715919629&_gaz=1&gcd=13l3l3l2l1&npa=1&dma_cps=sypham&dma=1&cid=658054844.1711715920&ul=en-us&sr=1280x1024&pscdl=noapi&_s=1&sid=1711715920&sct=1&seg=0&dl=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F03%2F26%2F2852084%2F0%2Fen%2FUnited-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html&dt=United%20States%20Food%20%26%20Drug%20Administration%20(FDA)%20Notifies&en=page_view&_fv=1&_nsi=1&_ss=1&_ee=1&tfd=1306 IP216.239.34.36:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerGoogle Trust Services LLC Subject*.google-analytics.com FingerprintDE:42:E4:CC:E5:66:70:09:F3:E6:6E:57:B7:5E:22:0A:A3:03:C2:7C ValidityMon, 26 Feb 2024 08:03:40 GMT - Mon, 20 May 2024 08:03:39 GMT
Hashd41d8cd98f00b204e9800998ecf8427e da39a3ee5e6b4b0d3255bfef95601890afd80709 e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
POST /g/collect?v=2&tid=G-ERWPGTJ5X8>m=45je43r0v9111814984za200&_p=1711715919629&_gaz=1&gcd=13l3l3l2l1&npa=1&dma_cps=sypham&dma=1&cid=658054844.1711715920&ul=en-us&sr=1280x1024&pscdl=noapi&_s=1&sid=1711715920&sct=1&seg=0&dl=https%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2024%2F03%2F26%2F2852084%2F0%2Fen%2FUnited-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html&dt=United%20States%20Food%20%26%20Drug%20Administration%20(FDA)%20Notifies&en=page_view&_fv=1&_nsi=1&_ss=1&_ee=1&tfd=1306 HTTP/1.1
Host: region1.analytics.google.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Content-Length: 0
HTTP/2 204 No Content
access-control-allow-origin: https://www.globenewswire.com
date: Fri, 29 Mar 2024 12:38:40 GMT
pragma: no-cache
expires: Fri, 01 Jan 1990 00:00:00 GMT
cache-control: no-cache, no-store, must-revalidate
access-control-allow-credentials: true
content-type: text/plain
cross-origin-resource-policy: cross-origin
server: Golfe2
content-length: 0
alt-svc: h3=":443"; ma=2592000,h3-29=":443"; ma=2592000
X-Firefox-Spdy: h2
|
|
| geolocation.onetrust.com/cookieconsentpub/v1/geo/location | 172.64.155.119 | 200 OK | 72 B |
URL GET HTTP/2geolocation.onetrust.com/cookieconsentpub/v1/geo/location IP172.64.155.119:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectonetrust.com Fingerprint9B:BC:B4:A8:C7:6C:6C:02:0F:FD:9F:06:F2:67:FB:DD:A1:E0:3F:47 ValidityMon, 13 Nov 2023 00:00:00 GMT - Tue, 12 Nov 2024 23:59:59 GMT
File typetroff or preprocessor input, ASCII text, with no line terminators Hashadf75b99dbbf416c627dfc5de30f9ad1 699f3845f7dfb3fa9968c2117b44c3f3eb728fff a0e4a8f457272bd17d07ae2e1e09731df6cc6fdc3ea9e32e713ef4a8a012fc27
GET /cookieconsentpub/v1/geo/location HTTP/1.1
Host: geolocation.onetrust.com
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: application/json
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: application/json
access-control-allow-origin: *
access-control-allow-headers: Content-Type
access-control-allow-methods: GET, OPTIONS
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
server: cloudflare
cf-ray: 86bfeb160ea756b9-OSL
content-encoding: gzip
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otCommonStyles.css | 104.19.177.52 | 200 OK | 22 kB |
URL GET HTTP/2cdn.cookielaw.org/scripttemplates/202310.1.0/assets/otCommonStyles.css IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
File typeASCII text, with very long lines (21778), with no line terminators Hash73bc4067d312180a1b19a4d883f42d6a ad328a9a572fbea43f295e7769835ff08f6ff1fd d3f7b0ec4de079928a999641e781e80f33597a392a561bc460276dfb4efb6eec
GET /scripttemplates/202310.1.0/assets/otCommonStyles.css HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: */*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
Referer: https://www.globenewswire.com/
Origin: https://www.globenewswire.com
DNT: 1
Connection: keep-alive
Sec-Fetch-Dest: empty
Sec-Fetch-Mode: cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: text/css
content-md5: c7xAZ9MSGAobGaTYg/Qtag==
last-modified: Thu, 26 Oct 2023 03:35:19 GMT
x-ms-request-id: cd0a89dd-001e-002f-0e0f-2f3448000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 68461
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb1769217131-OSL
content-encoding: gzip
X-Firefox-Spdy: h2
|
|
| cdn.cookielaw.org/logos/static/ot_close.svg | 104.19.177.52 | 200 OK | 651 B |
URL GET HTTP/2cdn.cookielaw.org/logos/static/ot_close.svg IP104.19.177.52:443
Requested byhttps://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html CertificateIssuerCloudflare, Inc. Subjectcookielaw.org FingerprintC9:7F:A3:0A:53:6E:A6:6C:2F:D0:E2:2C:F5:35:B4:BC:81:90:40:31 ValidityFri, 01 Mar 2024 00:00:00 GMT - Tue, 31 Dec 2024 23:59:59 GMT
File typeSVG Scalable Vector Graphics image Hash775913dc8267eb216d54c1e1dfe467b1 c6c68dea713afbe52666360532140507347a5d10 7f95ae3119579940ba6840a95abc442065d3a8412a8f6aff872ffdf86bcc8240
GET /logos/static/ot_close.svg HTTP/1.1
Host: cdn.cookielaw.org
User-Agent: Mozilla/5.0 (X11; Linux x86_64; rv:96.0) Gecko/20100101 Firefox/96.0
Accept: image/avif,image/webp,*/*
Accept-Language: en-US,en;q=0.5
Accept-Encoding: gzip, deflate, br
DNT: 1
Connection: keep-alive
Referer: https://www.globenewswire.com/
Sec-Fetch-Dest: image
Sec-Fetch-Mode: no-cors
Sec-Fetch-Site: cross-site
Pragma: no-cache
Cache-Control: no-cache
HTTP/2 200 OK
date: Fri, 29 Mar 2024 12:38:40 GMT
content-type: image/svg+xml
content-md5: pcXWFGpuVeSg/jVnYCseRg==
last-modified: Thu, 28 Mar 2024 19:49:54 GMT
x-ms-request-id: b0c3cb5c-601e-0006-1188-810a3c000000
x-ms-version: 2009-09-19
x-ms-lease-status: unlocked
x-ms-blob-type: BlockBlob
access-control-expose-headers: x-ms-request-id,Server,x-ms-version,Content-Type,Last-Modified,ETag,Content-MD5,x-ms-lease-status,x-ms-blob-type,Content-Length,Date,Transfer-Encoding
access-control-allow-origin: *
cache-control: max-age=86400
cf-cache-status: HIT
age: 23171
vary: Accept-Encoding
strict-transport-security: max-age=31536000; includeSubDomains; preload
x-content-type-options: nosniff
server: cloudflare
cf-ray: 86bfeb1798ccb509-OSL
content-encoding: gzip
X-Firefox-Spdy: h2
|
|